GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Motilal Oswal Nifty Midcap 150 Index Fund (G) 7.50 26,048 0.38 Motilal Oswal Nifty Midcap 150 Index Fund-Dir (G) 7.50 26,048 0.38 UTI-Nifty Midcap 150 Quality 50 Index Fund (G) 6.07 21,061 2.53 ...

At close: April 4 at 3:30:03 PM GMT+5:30 ...